A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2
27
about 3.4 years
18+
4 sites in CA, MI, OH +1
What this study is about
This trial is testing a treatment called MT-4561 in people with advanced solid tumors. The goal is to see if it's safe, how well the body processes it, and whether it works. This is a Phase 1/2 trial that will last about 1 year.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MT-4561
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of Adverse Event, Dose limiting toxicities (DLTs), Number of Patients with Adverse events (AEs)
Secondary: Best overall response (BoR), Clinical benefit rate (CBR), Cmax of MT-4561, Disease control rate (DCR), Duration of Response (DoR), Objective Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS)
Oncology